Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Arrowhead Pharmaceuticals (ARWR): Expanding Its RNAi Platform Amid Key Catalysts

Arrowhead Pharmaceuticals (ARWR): Expanding Its RNAi Platform Amid Key Catalysts

Key Takeaways

  • Regulatory expansion is the near-term engine: Arrowhead is expected to file a supplemental New Drug Application (sNDA) for plozasiran (REDEMPLO) in severe hypertriglyceridemia (SHTG) before the end of 2026, with a potential accelerated launch as early as mid-2027.
  • Obesity represents a pivotal, higher-upside opportunity: Data from the ARO-INHBE and ARO-ALK7 programs targeting weight loss through RNA interference (RNAi, a mechanism that silences disease-causing genes) are expected to shape the development path in 2026–2027.
  • Strategic positioning is anchored on a validated platform: The company's proprietary TRiM (Targeted RNAi Molecule) technology and a now commercial-stage cardiometabolic franchise give it a differentiated foothold in a competitive RNAi field.
  • Analyst sentiment is broadly constructive: Sell-side coverage carries a consensus "Strong Buy" rating, with an average 12-month price target near $107–$108 and a range spanning roughly $74 to $126, reflecting optimism about the pipeline rather than current profitability.
  • Key macro sensitivities: As a pre-profitability biotech, Arrowhead's valuation remains sensitive to interest rates, capital-market liquidity, and healthcare policy, while its cash position of about $1.6 billion provides a multi-year runway.
  • Risks to watch: Clinical and regulatory execution risk, competition from other RNAi and lipid-lowering developers, and the company's still-negative earnings profile could alter the outlook.

Strategic Positioning and Competitive Outlook

Arrowhead Pharmaceuticals has transitioned from a pure clinical-stage developer into a commercial-stage RNAi company, a shift that reshapes its medium-term market positioning. Its lead asset, REDEMPLO (plozasiran), is the first and only small interfering RNA (siRNA) therapy approved for familial chylomicronemia syndrome (FCS), a rare genetic disorder causing dangerously elevated triglycerides. Regulatory approvals now span the United States, the European Union, the United Kingdom, Canada, China, and Australia, with the company retaining commercialization rights in most geographies.

The broader strategic value lies in Arrowhead's TRiM platform, which enables precise gene silencing across multiple tissue types, including the liver, lung, muscle, and central nervous system. This versatility underpins a pipeline of roughly 23 clinical candidates and has attracted collaborations with major pharmaceutical partners, including Novartis and Sarepta. Structurally, the company is positioning itself as an emerging cardiometabolic franchise, planning to expand plozasiran into the much larger SHTG population while advancing early-stage obesity and central nervous system programs. From what I see, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Major Catalysts Ahead

The most consequential near-term catalyst is the planned sNDA filing for plozasiran in SHTG, supported by positive Phase 3 results from the SHASTA-3 and SHASTA-4 trials. Those studies reported median triglyceride reductions of roughly 79% and 81% versus about 27% for placebo, along with a 78% reduction in acute pancreatitis events. Arrowhead has acquired a priority review voucher intended to compress U.S. regulatory review, potentially enabling a launch as early as the second quarter of 2027.

Beyond SHTG, investors are watching the ARO-INHBE and ARO-ALK7 obesity candidates, which target a high-quality weight-loss profile with improved body composition. Additional data are anticipated through 2026, and management has signaled intentions to align with regulators on next steps. Separately, the ARO-DIMER-PA program, which combines PCSK9 and APOC3 targeting for mixed hyperlipidemia, and the zodasiran program for homozygous familial hypercholesterolemia (HoFH) represent further pipeline catalysts into 2027. I’m watching this closely as analyst activity has been notably optimistic, with Morgan Stanley upgrading ARWR to Overweight, while UBS and J.P. Morgan initiated coverage with Buy or Overweight ratings. Firms including Piper Sandler, B. Riley Securities, and H.C. Wainwright have set price targets above $120. The overall trajectory of analyst ratings and price targets has become more constructive through 2026, reflecting growing confidence in the cardiometabolic and obesity franchises.

Industry and Macroeconomic Forces

Arrowhead's trajectory is shaped by several macro forces. As a pre-profitability biotechnology company, its valuation is sensitive to interest rates: higher long-term yields raise the discount rate applied to future cash flows, while a more accommodative rate environment typically supports growth-stage biotech multiples. Broader capital-market liquidity also influences financing conditions and appetite for strategic partnerships and merger-and-acquisition activity across the sector.

On the policy side, drug-pricing dynamics, including provisions of the Inflation Reduction Act in the United States, and evolving payer-reimbursement frameworks in Europe could affect the commercial economics of new launches. Industry-wide, the obesity and cardiometabolic markets remain intensely competitive, with multiple developers pursuing RNAi, peptide, and small-molecule approaches, which raises the bar for differentiation on efficacy, safety, and dosing convenience.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Arrowhead's long-term narrative centers on the breadth of its RNAi platform and its expansion from rare diseases into larger markets. Successfully broadening plozasiran into SHTG would materially expand the addressable patient population and begin to test the company's commercial infrastructure at scale. The obesity programs represent a structurally larger, but earlier-stage, opportunity where differentiated safety and body-composition data could justify meaningful long-term value.

Cost-structure evolution and margin sustainability will be closely scrutinized as the company scales its commercial organization. While revenue is projected to decline from the elevated partnership-driven level of fiscal 2025, and the company is expected to remain unprofitable in the near term, a cash balance of approximately $1.6 billion offers runway through a catalyst-rich period. Capital-allocation priorities, including disciplined spending and selective partnering, will be central to preserving that runway.

Longer-term themes include the transition of RNAi beyond the liver into central nervous system and muscle tissue, where programs such as ARO-MAPT and ARO-SNCA could open entirely new therapeutic categories. Competitive threats from other RNAi and cardiometabolic players, regulatory developments, and the pace of obesity data maturation will continue to shape consensus expectations. While external analyst price targets cluster well above current levels, they should be read as independent forecasts reflecting pipeline optimism rather than guaranteed outcomes.

Exploring AI Tools for Market Insights

In my analysis of names like ARWR, I often turn to Tickeron’s AI Trend Prediction Engine as a complementary signal. This AI-powered forecasting tool helps assess whether a stock may trend bullish, bearish, or sideways over the coming week or month, offering searchable prediction categories and historical context to support more timely decision-making alongside fundamental research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARWR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ARWR sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for ARWR moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In 83 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for ARWR entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in 222 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.647) is normal, around the industry mean (3.498). P/E Ratio (-25.509) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Industry
Biotechnology
Address
177 E Colorado Boulevard
Phone
+1 626 304-3400
Employees
711
Web
https://www.arrowheadpharma.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.